Our pipeline

Product candidate
Cancer Indication
Combination with
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Next expected event
Combination w/
pemetrexed/cisplatin
1H 2021
Survival updates
Combination w/Keytruda
1H 2021
Immune data
ONCOS-102
Collaborators: Ludwig, CRI & AstraZeneca Combination w/Imfinzi
Update by collaborator
ONCOS-102
Collaborator: Sotio
Combination w/DCvac
Update by collaborator
Next Gen viruses
-
Updates at conferences
Novel mutRAS concepts
-
Updates at conferences
Cancer Indication: Mesothelioma
Combination with: Combination w/
pemetrexed/cisplatin

Product candidate: ONCOS-102
Next expected event: 1H 2021, Survival updates
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Melanoma
Combination with: Combination w/Keytruda
Product candidate: ONCOS-102
Next expected event: 1H 2021, Immune data
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Colorectal
Combination with: Collaborators: Ludwig, CRI & AstraZeneca Combination w/Imfinzi
Product candidate: ONCOS-102
Next expected event: Update by collaborator
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Prostate
Combination with: Collaborator: Sotio Combination w/DCvac
Product candidate: ONCOS-102
Next expected event: Update by collaborator
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication: Next Gen viruses
Combination with: -
Product candidate: ONCOS-200 series
Updates at conferences
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Cancer Indication:
Combination with: -
Product candidate: Novel mutRAS concepts
Discovery
Preclinical
Phase 1
Phase 2
Phase 3